Alignment Healthcare, Inc. Common Stock
ALHC
$16.35
-0.12%
Alignment Healthcare, Inc. is a technology-driven healthcare company focused on providing Medicare Advantage plans to seniors through a direct-to-consumer platform. It operates as a niche player in the managed care sector, distinguishing itself by combining a proprietary technology platform with a clinical model aimed at improving health outcomes and member experience. The current investor narrative is dominated by a significant positive regulatory catalyst—the recent larger-than-expected Medicare Advantage payment rate increase for 2027 announced by CMS—which has improved the sector's revenue outlook, alongside the company's upcoming inclusion in the S&P SmallCap 600 index, which is expected to enhance its institutional profile.…
ALHC
Alignment Healthcare, Inc. Common Stock
$16.35
Related headlines
ALHC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $21.26 and implied upside of +30.0% versus the current price.
Average Target
$21.26
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$13 - $21
Analyst target range
Analyst coverage is limited, with only 3 analysts providing estimates, indicating this is a smaller-cap stock with less institutional research scrutiny, which can contribute to higher volatility and less efficient price discovery. The average revenue estimate for the next year is $13.65 billion, with a range from $13.39 billion to $14.10 billion, reflecting a relatively tight spread of about 5% around the consensus, which suggests moderate uncertainty or stronger agreement on the company's near-term growth trajectory, likely anchored by the visible Medicare Advantage enrollment trends and recent CMS payment news.
Bulls vs Bears: ALHC Investment Factors
The bull and bear cases for ALHC are sharply divided, with the bear side currently holding stronger evidence due to the stock's severe price breakdown, erratic profitability, and high leverage. The bulls point to powerful regulatory catalysts, robust growth, and a deeply oversold condition suggesting a potential rebound. The single most important tension in the investment debate is whether the company's strong revenue growth (44.43% YoY) can soon translate into consistent profitability before its financial leverage (Debt/Equity of 1.89) and cash burn become unsustainable. The resolution of this profitability puzzle will determine if the stock's discounted forward PS of 0.29 is a value trap or a compelling opportunity.
Bullish
- Strong Regulatory Catalyst: The recent larger-than-expected Medicare Advantage payment rate increase for 2027 from CMS provides a significant boost to sector-wide revenue visibility. This directly improves the long-term financial outlook for ALHC's core business model, which is entirely focused on Medicare Advantage plans.
- Robust Revenue Growth Trajectory: The company is delivering strong top-line expansion, with Q4 2025 revenue of $1.01 billion representing 44.43% year-over-year growth. Analyst consensus projects next year's revenue to reach $13.65 billion, implying continued significant scale-up from the current run-rate.
- Deeply Oversold Technical Condition: The stock is trading at $15.73, near the bottom of its 52-week range ($11.625 to $23.87), having fallen 24.81% in the past month. This extreme negative momentum has created a potential technical setup for a bounce, especially with a beta of 1.27 amplifying potential upside moves.
- Index Inclusion Boosts Profile: Upcoming inclusion in the S&P SmallCap 600 index is a positive milestone that should increase institutional ownership and trading liquidity. This structural change can provide a non-fundamental tailwind and reduce the stock's volatility premium over time.
Bearish
- Erratic Path to Profitability: The company's earnings are highly inconsistent, swinging from a $15.7M net income in Q2 2025 to an $11.0M loss in Q4 2025. This volatility, coupled with a low gross margin of 10.47% in the latest quarter, raises serious questions about its ability to achieve sustainable profitability.
- Severe Negative Momentum & Underperformance: ALHC has dramatically underperformed the market, down 24.81% over the past month versus the S&P 500's 5.6% gain, resulting in a relative strength of -30.41. This accelerating downtrend indicates a fundamental breakdown in investor confidence that may not be easily reversed.
- High Financial Leverage & Cash Burn: The company carries a high debt-to-equity ratio of 1.89 and generated negative free cash flow of -$66.6M in the last quarter. Despite a $577.9M cash balance, this reliance on external financing and cash burn constrains financial flexibility if operational losses persist.
- Revenue Growth Deceleration: While YoY revenue growth of 44.43% is strong, it marks a significant sequential deceleration from the 101.5% growth seen in Q2 2025. This moderating pace as the company laps tougher comparisons suggests the hyper-growth phase may be ending, which could pressure the valuation multiple.
ALHC Technical Analysis
The stock is in a pronounced downtrend, having declined 24.81% over the past month and 22.09% over the past three months, which starkly contrasts with the S&P 500's gains of 5.6% and 8.42% over the same periods, respectively. With a current price of $15.73, the stock is trading at approximately 34% of its 52-week range ($11.625 to $23.87), positioning it much closer to its yearly low, which suggests deep oversold conditions but also reflects significant negative momentum and investor pessimism. Recent momentum is decisively negative and accelerating, as evidenced by the 1-month drop of 24.81% far exceeding the 1-year gain of 5.57%, indicating a sharp reversal from any prior strength and signaling a breakdown in the longer-term trend, with the stock's relative strength of -30.41 against the market underscoring severe underperformance. Key technical support is at the 52-week low of $11.625, while resistance lies near the recent breakdown level and the 52-week high of $23.87; a sustained break below support could trigger further selling, while a recovery above the $18-$20 zone would be needed to signal a potential reversal, with the stock's beta of 1.27 indicating it is 27% more volatile than the broader market, amplifying both downside and potential upside moves.
Beta
1.27
1.27x market volatility
Max Drawdown
-36.4%
Largest decline past year
52-Week Range
$12-$24
Price range past year
Annual Return
+12.8%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | -22.2% | +4.8% |
| 3m | -20.6% | +8.2% |
| 6m | -2.1% | +13.1% |
| 1y | +12.8% | +27.9% |
| ytd | -19.1% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Revenue growth is robust but shows signs of sequential deceleration; the most recent quarterly revenue was $1.013 billion, representing a strong 44.43% year-over-year increase, yet this marks a slowdown from the 101.5% YoY growth seen in Q2 2025, indicating that while expansion continues, the pace is moderating as the company laps tougher comparisons. The company's path to profitability is inconsistent; it reported a net loss of $11.0 million in Q4 2025, following two quarters of net income ($3.7M in Q3, $15.7M in Q2), with a gross margin of 10.47% in that quarter, which is low for the managed care sector and highlights ongoing cost pressures despite the significant revenue scale. Balance sheet and cash flow health is mixed; the company holds a substantial cash balance of $577.9 million and has a current ratio of 1.74, indicating good short-term liquidity, but it generated negative free cash flow of -$66.6 million in the last quarter and carries a high debt-to-equity ratio of 1.89, suggesting reliance on external financing and elevated financial leverage that could constrain flexibility if losses persist.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.44%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.99, while the forward-looking valuation is implied by the market cap relative to next year's estimated revenue of $13.65 billion, resulting in a forward PS of approximately 0.29, indicating the market expects significant revenue growth to continue. Compared to industry averages, the stock's trailing PS of 0.99 is difficult to benchmark directly without a provided sector average, but a sub-1x sales multiple for a high-growth healthcare company could suggest a discount, potentially reflecting concerns over its path to profitability and recent operational volatility. Historically, the stock's own PS ratio has fluctuated widely; the current 0.99 is near the lower end of its historical range observed in recent quarters (e.g., 3.86 in Q4 2025, 1.48 in Q1 2024), suggesting the market is currently pricing in a more pessimistic scenario regarding growth sustainability and margin prospects than in the past.
PE
-5401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -99x~233x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. ALHC's path to profitability is highly inconsistent, as evidenced by its swing from a $15.7M net income in Q2 to an $11.0M loss in Q4 2025. Its gross margin of 10.47% is low for the managed care sector, indicating significant underlying cost pressures. The company carries a high debt-to-equity ratio of 1.89 and burned -$66.6M in free cash flow last quarter, creating reliance on its $577.9M cash balance and external financing. Revenue concentration in Medicare Advantage plans, while benefiting from the CMS catalyst, also creates single-point regulatory and competitive risk.
Market & Competitive Risks are elevated. The stock's severe underperformance (relative strength of -30.41 over 1 month) and high beta of 1.27 indicate it is highly sensitive to market sentiment and prone to sharp downdrafts. Trading near its 52-week low, the stock faces valuation compression risk if growth decelerates further, as its forward PS of ~0.29 suggests the market already expects significant challenges. As a niche player, it faces intense competition from larger, more profitable rivals like UnitedHealth and Humana, which have greater scale and pricing power. The limited analyst coverage (only 3 analysts) exacerbates volatility and sentiment-driven price moves.
The Worst-Case Scenario involves a continuation of operational missteps leading to sustained losses. A specific chain could be: Q2 2026 earnings miss on both revenue and profitability, gross margins compress further below 10%, and negative free cash flow accelerates, depleting the cash balance faster than expected. This could trigger debt covenant concerns, forced equity dilution, and a loss of investor confidence in the growth story. In this adverse scenario, the stock could realistically re-test its 52-week low of $11.625, representing a downside of approximately -26% from the current price of $15.73, with potential for further declines given the stock's history of a -41.15% max drawdown.